SERA - רווח נקי למניה (EPS TTM) Sera Prognostics, Inc.

Sera Prognostics is implementing AI-driven proteomics analytics for prenatal screening. The company's business moat is based on patents and unique databases. Net income per share over the last 12 months reflects capital dynamics, where the -0.66 level serves as a critical benchmark. Currently, Sera Prognostics is scaling its diagnostics for preterm birth, aiming to integrate its tests into US insurance standards.

This indicator measures the portion of net profit attributable to a single common share per year, allowing for an assessment of the business's real yield without accounting for capital dilution. An analysis of the net income per share over 12 months confirms the operational resilience of Sera Prognostics (SERA), taking into account the costs of transitioning to eco-friendly packaging and the reduction of plastic in diagnostic systems.